Form 4: Caris Life Sciences Executive Sells Shares

David Spetzler, President of Caris Life Sciences, Inc., reported a transaction involving the sale of 13,856 shares of common stock.

Summary

• David Spetzler, President of Caris Life Sciences, Inc., reported a transaction on May 15, 2026.
• The transaction involved the disposal of 13,856 shares of common stock.
• These shares were withheld for the payment of taxes related to the vesting and settlement of Restricted Stock Units (RSUs).
• Following this transaction, Spetzler beneficially owns 530,083 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine tax settlement related to RSU vesting rather than a discretionary sale or purchase of stock.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock dealings. This specific filing details a common event where shares are used to cover tax liabilities upon RSU vesting.

Key Dates

Keywords

Caris Life Sciences, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Payment, David Spetzler, President